Literature DB >> 3141155

Postoperative prophylaxis with norfloxacin in patients requiring bladder catheters.

H A Verbrugh1, A J Mintjes-de Groot, R Andriesse, K Hamersma, A van Dijk.   

Abstract

The effect of once daily doses of 200 mg oral norfloxacin on the occurrence of catheter-associated bacteriuria (greater than 1000 CFU/ml) and pyuria was studied in 105 post-operative gynaecologic patients. Norfloxacin was given from the second day after surgery until catheter removal. Bacteriuria developed in 32 of 51 (63%) control patients compared to 8 of 54 (15%) patients receiving norfloxacin (p less than 0.001). Pyuria was present in 22 of 51 (43%) control subjects versus only 3 of 54 (5%) patients treated with norfloxacin (p less than 0.001). Bacteria isolated from control patients comprised species of Enterobacteriaceae (40%), Staphylococcus (35%), and Streptococcus (17%); seven isolates were resistant to multiple antibiotics reflecting their nosocomial origin. In contrast, strains isolated from norfloxacin-treated patients comprised non-fermenting gram-negative rods (79%, usually Alcaligenes or Acinetobacter spp.) and faecal streptococci (12%). It is concluded that once daily doses of 200 mg oral norfloxacin are effective in reducing the rate of catheter-associated bacteriuria and pyuria following reconstructive gynaecologic surgery.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141155     DOI: 10.1007/bf01962598

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  32 in total

1.  PREVENTION OF URINARY INFECTION IN GYNAECOLOGY.

Authors:  W A GILLESPIE; G G LENNON; K B LINTON; N SLADE
Journal:  Br Med J       Date:  1964-08-15

2.  Factors predisposing to bacteriuria during indwelling urethral catheterization.

Authors:  R A Garibaldi; J P Burke; M L Dickman; C B Smith
Journal:  N Engl J Med       Date:  1974-08-01       Impact factor: 91.245

3.  Prevention of catheter-induced urinary-tract infections by sterile closed drainage.

Authors:  C M Kunin; R C McCormack
Journal:  N Engl J Med       Date:  1966-05-26       Impact factor: 91.245

4.  Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

Authors:  J E Karp; W G Merz; C Hendricksen; B Laughon; T Redden; B J Bamberger; J G Bartlett; R Saral; P J Burke
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

5.  Use of norfloxacin in the treatment of acute diarrheal disease.

Authors:  H L Dupont; M L Corrado; J Sabbaj
Journal:  Am J Med       Date:  1987-06-26       Impact factor: 4.965

6.  Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery.

Authors:  M Grabe; A Forsgren; T Björk; S Hellsten
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

7.  Indwelling catheter infection.

Authors:  A G Keresteci; W D Leers
Journal:  Can Med Assoc J       Date:  1973-10-20       Impact factor: 8.262

8.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

10.  Randomised clinical trial of perioperative cefazolin in preventing infection after hysterectomy.

Authors:  B F Polk; I B Tager; M Shapiro; B Goren-White; P Goldstein; S C Schoenbaum
Journal:  Lancet       Date:  1980-03-01       Impact factor: 79.321

View more
  1 in total

1.  Use of norfloxacin for prevention of symptomatic urinary tract infection in chronically catheterized patients.

Authors:  O T Rutschmann; A Zwahlen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.